Patrys Limited Faces Delay in PAT-DX1 Drug Development

Patrys Limited (AU:PAB) has released an update.

Patrys Limited reports a delay in the GMP manufacturing run of its cancer-targeting antibody drug PAT-DX1, due to a process inconsistency in specification testing at their Contract Development Manufacturing Organization. The issue is being addressed, with testing and potential drug release for clinical trials now expected in the second half of August 2024. This setback impacts the timeline for initiating clinical development for PAT-DX1, a promising treatment for various cancers.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.